Summary

The global artificial intelligence (AI) in healthcare market is projected to reach USD 194.79 billion by 2031 from USD 36.67 billion in 2026, at a CAGR of 39.7% during the forecast period. The AI in healthcare market is growing rapidly as hospitals and health systems increasingly deploy AI solutions to improve clinical efficiency, reduce physician burnout, and enhance patient outcomes. For example, in 2025, the Cleveland Clinic rolled out Ambience Healthcare’s AI documentation platform across its US outpatient network after evaluating the technology across more than 80 specialties. The solution was adopted by over 4,000 clinicians within 15 weeks of deployment, enabling documentation for more than one million patient encounters. Additionally, in January 2026, Aultman Health System deployed Nabla’s ambient AI solution across hundreds of clinicians through integration with Oracle Cerner, while AtlantiCare reported a 50% reduction in documentation time after implementing Oracle Health’s Clinical AI Agent. As real-world adoption continues to expand across hospitals, clinics, and health systems, AI is expected to play an increasingly critical role in shaping the future of healthcare delivery worldwide.

By deployment, the cloud-based models segment is expected to register the highest growth during the forecast period.
The AI in healthcare market is categorized into three deployment models: on-premises, cloud-based, and hybrid. The cloud-based models segment holds the largest share due to their scalability, cost-effectiveness, and accessibility. Cloud-based models facilitate real-time data processing and collaboration. They enable seamless integration, secure data storage, and rapid deployment, making them particularly well-suited for healthcare providers and payers. They provide faster, more reliable care while maintaining high-quality standards. Cloud-based AI solutions are becoming increasingly popular due to their cost-effectiveness, scalability, and support for remote access. These solutions enable seamless integration and real-time analytics. The growing adoption of telehealth and advancements in healthcare IT infrastructure further drive the demand for cloud-based models.

By end user, the hospitals & clinics segment dominated the artificial intelligence (AI) in healthcare market for healthcare providers in 2025.
By end user, the artificial intelligence (AI) in healthcare market for healthcare providers is segmented into hospitals & clinics, ambulatory surgical centers, home healthcare agencies & assisted living facilities, diagnostic & imaging centers, pharmacies, and other healthcare providers. The hospitals & clinics segment accounted for the largest share of the artificial intelligence (AI) in healthcare market for healthcare providers. This is attributed to the increasing demand for personalized medicines, precise diagnostics & surgical planning, growth in minimally invasive procedures, and the requirement for interoperability with existing systems. AI-based healthcare solutions enhance diagnostic accuracy, streamline operations, and personalize care in hospitals and clinics. They automate administrative tasks, predict patient outcomes, and enable faster decision-making with real-time data analysis. AI also supports remote monitoring, optimizes resources, and reduces costs by minimizing unnecessary treatments.

The Asia Pacific is expected to register the highest growth during the forecast period.
The artificial intelligence (AI) in healthcare market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is the fastest growing in the AI in healthcare market, driven by rapid healthcare digitalization, increasing investments in artificial intelligence, expanding adoption of electronic health records (EHRs), and strong government support for digital health initiatives. Countries such as China, India, Singapore, Japan, and South Korea are actively integrating AI into diagnostics, medical imaging, clinical decision support, and hospital workflow management. For instance, in February 2026, India launched its Strategy for AI in Healthcare (SAHI), establishing a national framework for the responsible and large-scale adoption of AI across the healthcare ecosystem. Healthcare providers across the region are also expanding AI adoption. In Singapore, the Ministry of Health is scaling generative AI for clinical documentation and AI-powered imaging solutions across the public healthcare system, while hospitals such as Ng Teng Fong General Hospital are using AI-enabled tools to improve patient management and care delivery.

The breakdown of primary participants is as mentioned below:
• By Company Type: Tier 1 (32%), Tier 2 (44%), and Tier 3 (24%)
• By Designation: Directors (30%), Managers (34%), and Others (36%)
• By Region: North America (40%), Europe (28%), Asia Pacific (20%), Latin America (7%), and the Middle East & Africa (5%)
Key Players
The prominent players operating in the artificial intelligence (AI) in healthcare market include Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), Epic Systems Corporation (US), GE Healthcare (US), Medtronic (US), Oracle (US), Veradigm LLC (US), Merative (IBM) (US), Google (US), Cognizant (US), Johnson & Johnson (US), Amazon Web Services, Inc. (US), SOPHiA GENETICS (US), Riverian Technologies (US), Terarecon (ConcertAI) (US), Solventum Corporation (US), Tempus (US), Viz.ai (US). These companies adopted strategies such as product launches, product updates, expansions, partnerships, collaborations, mergers, and acquisitions to strengthen their market presence in the artificial intelligence (AI) in healthcare market.
Research Coverage
The report analyzes the artificial intelligence (AI) in healthcare market and estimates the market size and future growth potential of various market segments by offering, function, application, deployment model, tool, end user, and region. The report also analyses factors (such as drivers, restrains, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges for market stakeholders. The report also examines micromarkets in terms of their growth trends, prospects, and contributions to the total artificial intelligence (AI) in healthcare market. The report forecasts revenue for the market segments across five major regions. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will help established firms, as well as new entrants/smaller firms, gauge the market pulse, which, in turn, will help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market positions.
This report provides insights on:
• Analysis of key drivers (rapid proliferation of AI in healthcare sector and growing need for improved healthcare services), restraints (shortage of skilled AI professionals handling AI-powered solutions and lack of standardized frameworks for AI and ML technologies), opportunities (strategic partnerships and collaborations among healthcare companies and AI technology providers and increase in focus on developing human-aware AI systems), challenges (concerns regarding data privacy and lack of interoperability) are factors contributing the growth of the artificial intelligence (AI) in healthcare market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and software launches in the artificial intelligence (AI) in healthcare market.
• Market Development: Comprehensive information on the lucrative emerging markets, offering, function, application, deployment, tool, end user, and region
• Market Diversification: Exhaustive information about software portfolios, growing geographies, recent developments, and investments in the artificial intelligence (AI) in healthcare market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global artificial intelligence (AI) in healthcare market, such as Koninklijke Philips N.V. (Netherlands), Microsoft Corporation (US), Siemens Healthineers AG (Germany), NVIDIA Corporation (US), and Epic Systems Corporation (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 66
1.1 STUDY OBJECTIVES 66
1.2 MARKET DEFINITION 66
1.3 MARKET SCOPE 67
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 67
1.3.2 INCLUSIONS AND EXCLUSIONS 68
1.3.3 YEARS CONSIDERED 71
1.4 CURRENCY CONSIDERED 72
1.5 STAKEHOLDERS 72
2 EXECUTIVE SUMMARY 73
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 73
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 75
2.3 DISRUPTIVE TRENDS IN AI IN HEALTHCARE MARKET 76
2.4 HIGH-GROWTH SEGMENTS 77
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 78
3 PREMIUM INSIGHTS 79
3.1 AI IN HEALTHCARE MARKET OVERVIEW 79
3.2 AI IN HEALTHCARE MARKET, BY APPLICATION AND REGION 80
3.3 AI IN HEALTHCARE MARKET: GEOGRAPHIC SNAPSHOT 80
4 MARKET OVERVIEW 81
4.1 INTRODUCTION 81
4.2 MARKET DYNAMICS 81
4.2.1 DRIVERS 82
4.2.1.1 Increasing need for early detection and diagnosis of diseases 82
4.2.1.2 Exponential growth in data volume and complexity due to surging adoption of digital technologies 83
4.2.1.3 Significant cost pressure on healthcare service providers with increasing prevalence of chronic diseases 84
4.2.1.4 Rapid proliferation of AI in healthcare sector 84
4.2.1.5 Growing inclination toward precision medicine and personalized care 85
4.2.2 RESTRAINTS 86
4.2.2.1 Reluctance among medical practitioners to adopt AI-based technologies 86
4.2.2.2 Shortage of skilled AI professionals handling AI-powered solutions 86
4.2.2.3 Lack of standardized frameworks for AI and ML technologies 87
 
4.2.3 OPPORTUNITIES 87
4.2.3.1 Rising demand for AI-driven clinical decision support systems 87
4.2.3.2 Increasing focus on developing human-aware AI systems 88
4.2.3.3 Strategic partnerships and collaborations among healthcare companies and AI technology providers 89
4.2.3.4 Rising adoption of AI-enabled medical imaging and diagnostics 90
4.2.4 CHALLENGES 91
4.2.4.1 Inaccurate predictions due to scarcity of high-quality healthcare data 91
4.2.4.2 Concerns regarding data privacy 91
4.2.4.3 Lack of interoperability between AI solutions offered by different vendors 92
4.3 UNMET NEEDS AND WHITE SPACES 92
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 93
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 93
5 INDUSTRY TRENDS 94
5.1 PORTER’S FIVE FORCES ANALYSIS 94
5.1.1 THREAT OF NEW ENTRANTS 95
5.1.2 THREAT OF SUBSTITUTES 96
5.1.3 BARGAINING POWER OF SUPPLIERS 96
5.1.4 BARGAINING POWER OF BUYERS 96
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 96
5.2 MACROECONOMIC OUTLOOK 97
5.2.1 INTRODUCTION 97
5.2.2 GDP TRENDS AND FORECAST 97
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 97
5.3 VALUE CHAIN ANALYSIS 97
5.4 ECOSYSTEM ANALYSIS 99
5.5 PRICING ANALYSIS 100
5.5.1 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY APPLICATION (2025) 100
5.5.2 INDICATIVE PRICING FOR AI IN HEALTHCARE MARKET, BY REGION (2025) 101
5.6 KEY CONFERENCES AND EVENTS, 2026–2027 102
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 102
5.8 INVESTMENT AND FUNDING SCENARIO 103
5.9 CASE STUDY ANALYSIS 104
5.9.1 ACCELERATING LUNG CANCER DIAGNOSIS THROUGH AI ACROSS NHS HOSPITALS 104
5.9.2 STRENGTHENING PATIENT TRUST THROUGH DIGITAL PATIENT ENGAGEMENT SOLUTIONS 104
5.9.3 OPTIMIZING PATIENT ENGAGEMENT AND COMMUNICATION WITH TRUBRIDGE PATIENT CONNECT 105
 
5.10 IMPACT OF US TARIFF – OVERVIEW 105
5.10.1 INTRODUCTION 105
5.10.2 KEY TARIFF RATES 106
5.10.3 PRICE IMPACT ANALYSIS 107
5.10.4 IMPACT ON COUNTRIES/REGIONS 107
5.10.4.1 US 107
5.10.4.2 Europe 108
5.10.4.3 Asia Pacific 109
5.10.5 IMPACT ON END USERS 109
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 111
6.1 KEY EMERGING TECHNOLOGIES 111
6.1.1 MACHINE LEARNING AND DEEP LEARNING 111
6.1.2 NATURAL LANGUAGE PROCESSING 111
6.1.3 COMPUTER VISION 111
6.2 COMPLEMENTARY TECHNOLOGIES 112
6.2.1 CLOUD COMPUTING 112
6.2.2 DIGITAL TWINS 112
6.2.3 ROBOTIC PROCESS AUTOMATION 112
6.3 ADJACENT TECHNOLOGIES 112
6.3.1 BLOCKCHAIN 112
6.3.2 AUGMENTED REALITY AND VIRTUAL REALITY 113
6.3.3 INTERNET OF THINGS 113
6.4 PATENT ANALYSIS 113
6.4.1 PATENT PUBLICATION TRENDS FOR AI IN HEALTHCARE LANDSCAPE 113
6.4.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 114
6.5 FUTURE APPLICATIONS 116
6.5.1 AI-DRIVEN PRECISION MEDICINE 116
6.5.2 REAL-TIME CLINICAL DECISION SUPPORT WITH GENERATIVE AI 117
6.5.3 DISEASE PREDICTION AND EARLY INTERVENTION THROUGH PREDICTIVE ANALYTICS 117
6.5.4 AI-POWERED VIRTUAL HEALTH ASSISTANTS AND DIGITAL CARE NAVIGATION 117
6.5.5 ADVANCING AUTONOMOUS AI AGENTS FOR HEALTHCARE WORKFLOW AUTOMATION 117
7 REGULATORY LANDSCAPE 118
7.1 REGIONAL REGULATIONS AND COMPLIANCE 118
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118
7.1.2 REGULATORY FRAMEWORK 120
 
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 124
8.1 INTRODUCTION 124
8.2 DECISION-MAKING PROCESS 124
8.3 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 124
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 125
8.3.2 BUYING CRITERIA 125
8.4 ADOPTION BARRIERS AND INTERNAL CHALLENGES 126
8.5 UNMET NEEDS OF VARIOUS END USERS 127
8.5.1 UNMET NEEDS 127
8.5.2 END-USER EXPECTATIONS 128
8.6 MARKET PROFITABILITY 129
8.7 IMPACT ON COUNTRIES/REGIONS 130
8.7.1 US 130
8.7.2 EUROPE 131
8.7.3 ASIA PACIFIC 131
8.8 IMPACT ON END USERS 132
9 AI IN HEALTHCARE MARKET, BY FUNCTION 133
9.1 INTRODUCTION 134
9.2 DIAGNOSIS & EARLY DETECTION 134
9.2.1 PRE-SCREENING 135
9.2.1.1 Early detection, better outcomes, and cost-effective care associated with pre-screening to boost market 135
9.2.2 IVD 136
9.2.2.1 IVD market, by technology 137
9.2.2.1.1 Immunoassays 137
9.2.2.1.1.1 Potential to enhance biomarker detection and laboratory automation to accelerate demand 137
9.2.2.1.2 Clinical chemistry 138
9.2.2.1.2.1 Ability to improve laboratory efficiency and diagnostic accuracy to spur adoption 138
9.2.2.1.3 Molecular diagnostics 139
9.2.2.1.3.1 Pressing need to identify viral and bacterial pathogens in infectious diseases to facilitate adoption 139
9.2.2.2 IVD market, by application 140
9.2.2.2.1 Image analysis & interpretation 141
9.2.2.2.1.1 Rising focus of pathologists on analyzing tissue samples for detecting abnormalities at faster rate to fuel segmental growth 141
9.2.2.2.2 Biomarker discovery & analysis 142
9.2.2.2.2.1 Elevating adoption of precision medicine to create growth opportunities 142
9.2.2.2.3 Other IVD applications 142
 
9.2.3 DIAGNOSTIC IMAGING 143
9.2.3.1 Diagnostic imaging market, by application 144
9.2.3.1.1 Disease interpretation & report analysis 144
9.2.3.1.1.1 Proficiency in identifying disease-specific patterns and correlating findings across multiple data sources to fuel adoption 144
9.2.3.1.2 Image captioning & annotation 145
9.2.3.1.2.1 Increasing use of machine learning for automated image captioning to foster market growth 145
9.2.3.1.3 Image reconstruction 146
9.2.3.1.3.1 Greater emphasis of healthcare facilities on optimizing imaging workflows and increasing scanner throughput to augment adoption 146
9.2.3.1.4 Other diagnostic imaging applications 147
9.2.3.2 Diagnostic imaging market, by modality 148
9.2.3.2.1 Magnetic resonance imaging 148
9.2.3.2.1.1 Escalating adoption of AI across MRI workflows to enhance diagnostic confidence and improve scanner utilization to augment market growth 148
9.2.3.2.2 Computed tomography 149
9.2.3.2.2.1 Urgent need for efficient diagnosis to provide the right treatments to drive market 149
9.2.3.2.3 X-ray imaging 150
9.2.3.2.3.1 Development of innovative AI-based X-ray imaging solutions to drive market 150
9.2.3.2.4 Ultrasound 151
9.2.3.2.4.1 Increasing investments in developing AI-assisted ultrasound imaging auto-assessment tools to expedite market growth 151
9.2.3.2.5 Nuclear imaging 152
9.2.3.2.5.1 Integration of AI algorithms for quick detection and monitoring of abnormalities to facilitate market growth 152
9.2.3.2.6 Other diagnostic imaging modalities 153
9.2.4 RISK ASSESSMENT & PATIENT STRATIFICATION 154
9.2.4.1 Critical need to identify high-risk patients and predict their disease progression risks to boost demand 154
9.2.5 DRUG ALLERGY ALERTING 155
9.2.5.1 Significant focus on improving accuracy and speed of identifying allergic reactions to contribute to market growth 155
9.2.6 OTHER DIAGNOSIS & EARLY DETECTION FUNCTIONS 155
9.3 TREATMENT PLANNING & PERSONALIZATION 156
9.3.1 PERSONALIZED TREATMENT PLANNING 157
9.3.1.1 Precision medicine & genomic analysis 158
9.3.1.1.1 Adoption of AI-based software for personalized treatment decisions and improved outcomes to propel market 158
9.3.1.2 Predictive models for treatment response 159
9.3.1.2.1 Ability to personalize therapies, improve outcomes, and minimize adverse effects to fuel growth 159
9.3.1.3 Treatment recommendation systems 160
9.3.1.3.1 Competency in offering personalized, evidence-based treatment options to spike demand 160
9.3.2 PHARMACOLOGICAL THERAPY 161
9.3.2.1 Drug response prediction 162
9.3.2.1.1 Increasing use of AI-powered drug response prediction in oncology and chronic disease management to drive market 162
9.3.2.2 Dosing & administration 163
9.3.2.2.1 Capability of AI-based dosing models to adjust doses in real-time based on individual patient responses to spur demand 163
9.3.2.3 Other pharmacological therapy functions 164
9.3.3 SURGICAL THERAPY 164
9.3.3.1 Preoperative imaging & 3D modeling 165
9.3.3.1.1 Widening use of AI-driven 3D modeling in orthopedic, cardiovascular, neurological surgeries to fuel market growth 165
9.3.3.2 Intraoperative guidance & robotics 166
9.3.3.2.1 Inclination toward minimally invasive surgeries and faster patient recovery to boost implementation 166
9.3.3.3 Postoperative analysis & recovery 167
9.3.3.3.1 Ability to predict recovery patterns, identify risks, and provide personalized rehabilitation plans to boost demand 167
9.3.4 RADIATION THERAPY 168
9.3.4.1 Motion synchronization & auto contouring 169
9.3.4.1.1 Need for precise delivery of radiation and minimum exposure to surrounding healthy tissues to reinforce segmental growth 169
9.3.4.2 Real-time adaptive treatment delivery 170
9.3.4.2.1 Growing focus on consistent treatment accuracy and clinical outcome optimization to strengthen demand 170
9.3.4.3 Response assessment & quality assurance 171
9.3.4.3.1 Ability of AI solutions to analyze medical images, treatment plans, and dosimetric data to accelerate demand 171
9.3.4.4 Other radiation therapy functions 172
9.3.5 BEHAVIORAL THERAPY & PSYCHOTHERAPY 173
9.3.5.1 Virtual counseling & chatbots 174
9.3.5.1.1 Potential to improve patient communication, engagement, and service efficiency to expand implementation 174
9.3.5.2 Progress monitoring & feedback 175
9.3.5.2.1 Increasing use of smart wearables and mobile health apps to drive market 175
9.3.5.3 Follow-up & long-term support 175
9.3.5.3.1 Widespread adoption of telemedicine platforms to drive market expansion 175
 
9.3.6 IMMUNOTHERAPY 176
9.3.6.1 Real-time patient data monitoring 177
9.3.6.1.1 High demand for proactive healthcare management to foster segmental growth 177
9.3.6.2 Response & side-effect prediction 178
9.3.6.2.1 Need for earlier detection of treatment-related risks across drugs and vaccines to support segmental growth 178
9.3.6.3 Relapse prediction & long-term management 179
9.3.6.3.1 Necessity for continuous patient monitoring and risk stratification to fuel demand 179
9.3.7 OTHER TREATMENT PLANNING & PERSONALIZATION FUNCTIONS 180
9.4 PATIENT ENGAGEMENT & REMOTE MONITORING 181
9.4.1 SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE 182
9.4.1.1 Constant requirement for symptom management in chronic diseases to accelerate adoption of AI-powered apps 182
9.4.2 TELEHEALTH & REMOTE PATIENT MONITORING 183
9.4.2.1 Increasing adoption of mobile health apps and wearable devices to augment segmental growth 183
9.4.3 HEALTHCARE ASSISTANCE ROBOTS 184
9.4.3.1 Competency in improving quality of care and reducing burden on healthcare workers to promote adoption 184
9.4.4 MEDICATION REMINDERS 185
9.4.4.1 Capability to deliver medication guidance, personalized health coaching, and care coordination to foster demand 185
9.4.5 PATIENT EDUCATION & EMPOWERMENT 186
9.4.5.1 Need to improve treatment adherence and enhance self-management to drive market 186
9.4.6 OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS 187
9.5 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE 188
9.5.1 RECURRENCE MONITORING 189
9.5.1.1 Advancing post-treatment care through intelligent recurrence monitoring to support market growth 189
9.5.2 LONG-TERM OUTCOME PREDICTION 189
9.5.2.1 Greater emphasis on predicting disease recurrence and survival chances to improve uptake of AI-powered medical devices 189
9.5.3 MENTAL HEALTH & SUPPORT SYSTEMS 190
9.5.3.1 Rising focus on emotional well-being of patients with critical illness to support segmental growth 190
9.6 PHARMACY MANAGEMENT 191
9.6.1 EPRESCRIBING 192
9.6.1.1 Urgent need to replace paper-based prescription to electronic platform to expedite adoption of ePrescribing solutions 192
9.6.2 MEDICATION MANAGEMENT 193
9.6.2.1 Innovative medication management programs between healthcare professionals and pharmacists to encourage segmental growth 193
 
9.6.3 PHARMACY AUDIT & ANALYSIS 194
9.6.3.1 Demand for operational excellence and improved patient care outcomes across pharmacies to create growth opportunities 194
9.6.4 OTHER PHARMACY MANAGEMENT FUNCTIONS 195
9.7 DATA MANAGEMENT & ANALYTICS 196
9.7.1 RISING FOCUS OF HEALTHCARE ORGANIZATIONS ON DEVELOPING PERSONALIZED TREATMENT PLANS TO SUPPORT SEGMENTAL GROWTH 196
9.8 AI SCRIBE 196
9.8.1 GROWING NEED TO IMPROVE CLINICIAN PRODUCTIVITY AND REDUCE DOCUMENTATION TIME TO STRENGTHEN AI SCRIBE DEPLOYMENT 196
9.9 CLINICAL DECISION SUPPORT SYSTEMS 197
9.9.1 INCREASING NEED FOR EVIDENCE-BASED CLINICAL DECISION-MAKING TO SPIKE ADOPTION 197
9.10 ADMINISTRATIVE 198
9.10.1 PATIENT REGISTRATION & SCHEDULING 200
9.10.1.1 Rising adoption of self-service patient registration solutions to contribute to segmental growth 200
9.10.2 PATIENT ELIGIBILITY & AUTHORIZATION 201
9.10.2.1 Growing demand for faster prior authorization workflows to facilitate market growth 201
9.10.3 REVENUE CYCLE MANAGEMENT 201
9.10.3.1 Significant need to reduce claim denials and reimbursement delays to reinforce demand 201
9.10.4 WORKFORCE MANAGEMENT 202
9.10.4.1 Growing need to optimize healthcare workforce utilization to create lucrative opportunities 202
9.10.5 SUPPLY CHAIN & INVENTORY MANAGEMENT 203
9.10.5.1 Strong focus on reducing inventory costs and waste to bolster market growth 203
9.10.6 COMPLIANCE & DOCUMENTATION 204
9.10.6.1 Increasing regulatory compliance requirements in healthcare to escalate demand for AI-based compliance & documentation 204
9.10.7 HEALTHCARE WORKFLOW MANAGEMENT 205
9.10.7.1 Surging need for end-to-end workflow automation to foster segmental growth 205
9.10.8 ASSET MANAGEMENT 206
9.10.8.1 Pressing need to improve equipment availability and reduce downtime to heighten demand for AI-based asset management 206
9.10.9 CUSTOMER RELATIONSHIP MANAGEMENT 207
9.10.9.1 Growing focus on personalized patient engagement to boost segmental growth 207
9.10.10 FRAUD DETECTION & RISK MANAGEMENT 208
9.10.10.1 Rising financial losses to drive investment in AI-based proactive risk management solutions 208
 
9.10.11 CYBERSECURITY 209
9.10.11.1 Critical requirement to protect sensitive patient data to propel demand for AI-powered threat detection solutions 209
9.10.12 OTHER ADMINISTRATIVE FUNCTIONS 210
10 AI IN HEALTHCARE MARKET, BY OFFERING 211
10.1 INTRODUCTION 212
10.2 INTEGRATED SOLUTIONS 212
10.2.1 ESCALATING DEPLOYMENT OF ENTERPRISE-WIDE AI PLATFORMS TO CONTRIBUTE TO SEGMENTAL GROWTH 212
10.3 NICHE/POINT SOLUTIONS 213
10.3.1 GROWING ADOPTION OF SPECIALIZED AI APPLICATIONS FOR TARGETED CLINICAL AND ADMINISTRATIVE TASKS TO DRIVE MARKET 213
10.4 AI TECHNOLOGIES 214
10.4.1 HARNESSING AI FOR IMPROVED PATIENT OUTCOMES AND OPERATIONAL EFFICIENCY TO SUPPORT MARKET GROWTH 214
10.5 SERVICES 215
10.5.1 INCREASING FOCUS ON SEAMLESS AI DEPLOYMENT AND ONGOING SUPPORT TO FACILITATE SEGMENTAL GROWTH 215
11 AI IN HEALTHCARE MARKET, BY APPLICATION 217
11.1 INTRODUCTION 218
11.2 CLINICAL APPLICATIONS 218
11.2.1 NECESSITY TO ENHANCE PATIENT MONITORING AND CLINICAL DECISION-MAKING ABILITY TO SPUR DEMAND 218
11.3 NON-CLINICAL APPLICATIONS 220
11.3.1 REQUIREMENT TO ENHANCE OPERATIONAL EFFICIENCY, REDUCE ADMINISTRATIVE BURDEN, AND ENSURE BETTER RESOURCE ALLOCATION TO FOSTER MARKET GROWTH 220
12 AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL 222
12.1 INTRODUCTION 223
12.2 ON-PREMISES MODEL 223
12.2.1 CRITICALITY OF DATA PRIVACY AND SECURITY TO SUPPORT DEPLOYMENT OF ON-PREMISES HEALTHCARE INFRASTRUCTURE 223
12.3 CLOUD-BASED MODEL 224
12.3.1 RAPID SCALABILITY AND SECURE DATA HANDLING AND INTEGRATION ATTRIBUTES TO ELEVATE DEMAND FOR CLOUD-BASED AI SOLUTIONS IN HEALTHCARE 224
12.4 HYBRID MODEL 225
12.4.1 FOCUS OF HEALTHCARE ORGANIZATIONS ON PROTECTING DATA WITHOUT SACRIFICING SCALABILITY TO DRIVE SEGMENTAL GROWTH 225
 
13 AI IN HEALTHCARE MARKET, BY TOOL 227
13.1 INTRODUCTION 228
13.2 MACHINE LEARNING 228
13.2.1 DEEP LEARNING 230
13.2.1.1 Convolutional neural networks 231
13.2.1.1.1 Ability to analyze X-rays, CT scans, and MRIs with high precision to elevate adoption 231
13.2.1.2 Recurrent neural networks 232
13.2.1.2.1 Competency in analyzing sequential data to predict disease progression and treatment efficacy to boost deployment 232
13.2.1.3 Generative adversarial networks 233
13.2.1.3.1 Capability to generate synthetic data to train AI models and address data scarcity and privacy issues to propel demand 233
13.2.1.4 Graph neural networks 234
13.2.1.4.1 Ability to recommend personalized treatment to stimulate adoption 234
13.2.1.5 Other deep learning tools 235
13.2.2 SUPERVISED LEARNING 236
13.2.2.1 Growing importance of evidence-based decision-making in predictive and diagnostic tasks to spur demand 236
13.2.3 REINFORCEMENT LEARNING 237
13.2.3.1 Significance of precision medicine, value-based care, and intelligent clinical decision support to accelerate demand 237
13.2.4 UNSUPERVISED LEARNING 238
13.2.4.1 Increasing need to uncover hidden insights from unstructured healthcare data to boost adoption 238
13.2.5 OTHER MACHINE LEARNING TOOLS 238
13.3 NATURAL LANGUAGE PROCESSING 239
13.3.1 SENTIMENT ANALYSIS 241
13.3.1.1 Increasing adoption of AI for patient feedback analysis to contribute to market growth 241
13.3.2 PATTERN & IMAGE RECOGNITION 241
13.3.2.1 Growing utilization of AI for early disease detection and personalized treatment planning to facilitate market expansion 241
13.3.3 AUTO CODING 242
13.3.3.1 Elevating use of AI tools to improve claim reimbursement process to fuel market growth 242
13.3.4 CLASSIFICATION & CATEGORIZATION 243
13.3.4.1 Business need to organize and classify healthcare data efficiently to expand AI implementation 243
13.3.5 TEXT ANALYTICS 244
13.3.5.1 Necessity to derive insights from unstructured clinical text to enhance use of text analytics 244
 
13.3.6 SPEECH RECOGNITION 244
13.3.6.1 Rising focus on reducing physician administrative burden to accelerate demand 244
13.4 CONTEXT-AWARE COMPUTING 245
13.4.1 DEVICE CONTEXT 246
13.4.1.1 Integration of connected medical devices to boost demand for intelligent device-aware healthcare applications 246
13.4.2 USER CONTEXT 247
13.4.2.1 Rising focus on individualized clinical decision support to spike demand 247
13.4.3 PHYSICAL CONTEXT 248
13.4.3.1 Increasing adoption of AI for real-time environmental and patient context monitoring to generate demand 248
13.5 GENERATIVE AI 249
13.5.1 INCREASING USE OF GENERATIVE MODELS TO OFFER TAILORED INTERVENTIONS TO DRIVE MARKET 249
13.6 COMPUTER VISION 249
13.6.1 ABILITY TO DETECT ABNORMALITIES SUCH AS TUMORS AND FRACTURES TO FUEL ADOPTION 249
13.7 IMAGE ANALYSIS 251
13.7.1 GROWING ADOPTION OF AI FOR EARLY DISEASE DETECTION AND DIAGNOSIS TO CONTRIBUTE TO MARKT GROWTH 251
14 AI IN HEALTHCARE MARKET, BY END USER 252
14.1 INTRODUCTION 253
14.2 HEALTHCARE PROVIDERS 253
14.2.1 HOSPITALS & CLINICS 255
14.2.1.1 Increasing focus on enhancing patient outcomes through AI to expedite market expansion 255
14.2.2 AMBULATORY CARE CENTERS 256
14.2.2.1 Rising adoption of AI to reduce care delivery costs to reinforce market growth 256
14.2.3 HOME HEALTHCARE AGENCIES & ASSISTED-LIVING FACILITIES 257
14.2.3.1 Escalating demand for personalized and continuous patient care to accelerate market growth 257
14.2.4 DIAGNOSTIC & IMAGING CENTERS 258
14.2.4.1 Increasing partnerships between hospitals and imaging centers to develop regulatory-cleared AI tools to support market growth 258
14.2.5 PHARMACIES 259
14.2.5.1 Heightened need for AI-driven inventory optimization to unlock opportunities 259
14.2.6 OTHER HEALTHCARE PROVIDERS 260
 
14.3 HEALTHCARE PAYERS 260
14.3.1 PUBLIC PAYERS 262
14.3.1.1 Increasing focus on cost optimization and fraud prevention to promote adoption of AI by public payers 262
14.3.2 PRIVATE PAYERS 263
14.3.2.1 Leveraging AI to optimize claims management, member engagement, and value-based care programs to drive market 263
14.4 PATIENTS 264
14.4.1 INCREASING ADOPTION OF AI FOR PATIENT ENGAGEMENT AND SELF-CARE TO FACILITATE MARKET GROWTH 264
14.5 OTHER END USERS 265
15 AI IN HEALTHCARE MARKET, BY REGION 266
15.1 INTRODUCTION 267
15.2 NORTH AMERICA 267
15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 269
15.2.2 US 284
15.2.2.1 Increasing focus on personalized medicine and precision healthcare to drive market 284
15.2.3 CANADA 298
15.2.3.1 Rising use of AI to improve disease care and patient survival and clinical workflows to drive market 298
15.3 EUROPE 312
15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 312
15.3.2 GERMANY 327
15.3.2.1 Collaborative health-related research and innovation programs and initiatives to contribute to market growth 327
15.3.3 UK 340
15.3.3.1 Significant focus of government on early diagnosis, personalized treatments, and rapid drug development to boost AI demand 340
15.3.4 FRANCE 354
15.3.4.1 Expanding AI-enabled digital healthcare and patient services to foster market growth 354
15.3.5 ITALY 368
15.3.5.1 Growing deployment of AI infrastructure to ensure transparency, data protection, and patient safety to facilitate market growth 368
15.3.6 SPAIN 382
15.3.6.1 Partnerships between scientists, medical professionals, and AI experts to develop innovative diagnostic tools to drive market 382
15.3.7 REST OF EUROPE 395
 
15.4 ASIA PACIFIC 410
15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 411
15.4.2 CHINA 424
15.4.2.1 Growing focus on healthcare innovation through national AI initiatives to accelerate market growth 424
15.4.3 JAPAN 438
15.4.3.1 Strong healthcare infrastructure to drive adoption of advanced AI 438
15.4.4 INDIA 450
15.4.4.1 Strong government support for digital health initiatives to create lucrative opportunities 450
15.4.5 AUSTRALIA 464
15.4.5.1 Strong research ecosystem and national digital health initiatives to drive market 464
15.4.6 SOUTH KOREA 477
15.4.6.1 National Strategy for Artificial Intelligence and Digital Healthcare Innovation Plan initiatives to support market growth 477
15.4.7 REST OF ASIA PACIFIC 490
15.5 LATIN AMERICA 504
15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 504
15.5.2 BRAZIL 517
15.5.2.1 Expanding digital health infrastructure and growing adoption of AI-enabled healthcare technologies to foster market growth 517
15.5.3 MEXICO 530
15.5.3.1 Growing adoption of AI-driven chronic disease management platforms to stimulate market growth 530
15.5.4 REST OF LATIN AMERICA 543
15.6 MIDDLE EAST & AFRICA 556
15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 557
15.6.2 GCC 570
15.6.2.1 Saudi Arabia 583
15.6.2.1.1 Accelerating AI-driven healthcare transformation under Saudi Vision 2030 to contribute to market growth 583
15.6.2.2 UAE 596
15.6.2.2.1 Rising focus on improving healthcare quality and delivering personalized patient care to reinforce market growth 596
15.6.2.3 Rest of GCC 609
15.6.3 SOUTH AFRICA 622
15.6.3.1 Expanding use of AI to enhance medical imaging, clinical decision support, and disease surveillance to drive market 622
15.6.4 REST OF MIDDLE EAST & AFRICA 635
 
16 COMPETITIVE LANDSCAPE 649
16.1 INTRODUCTION 649
16.2 KEY PLAYER COMPETITIVE STRATEGY/RIGHT TO WIN, JANUARY 2023 TO JUNE 2026 649
16.3 REVENUE ANALYSIS, 2021–2025 652
16.4 MARKET SHARE ANALYSIS, 2025 653
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 655
16.5.1 STARS 655
16.5.2 EMERGING LEADERS 655
16.5.3 PERVASIVE PLAYERS 655
16.5.4 PARTICIPANTS 655
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 657
16.5.5.1 Company footprint 657
16.5.5.2 Region footprint 658
16.5.5.3 Application footprint 659
16.5.5.4 Tool footprint 660
16.5.5.5 Function footprint 661
16.5.5.6 Offering footprint 662
16.5.5.7 Deployment footprint 663
16.5.5.8 End user footprint 664
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 665
16.6.1 PROGRESSIVE COMPANIES 665
16.6.2 RESPONSIVE COMPANIES 665
16.6.3 DYNAMIC COMPANIES 665
16.6.4 STARTING BLOCKS 665
16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 667
16.6.5.1 Detailed list of key startups/SMEs 667
16.6.5.2 Company footprint (startups/SMEs) 667
16.7 COMPANY VALUATION AND FINANCIAL METRICS 668
16.7.1 FINANCIAL METRICS 668
16.7.2 COMPANY VALUATION 668
16.8 BRAND/PRODUCT COMPARISON 669
16.9 COMPETITIVE SCENARIO 669
16.9.1 PRODUCT LAUNCHES/ENHANCEMENTS/APPROVALS 669
16.9.2 DEALS 671
16.9.3 OTHER DEVELOPMENTS 672
 
17 COMPANY PROFILES 673
17.1 KEY PLAYERS 673
17.1.1 KONINKLIJKE PHILIPS N.V. 673
17.1.1.1 Business overview 673
17.1.1.2 Products & services offered 674
17.1.1.3 Recent developments 676
17.1.1.3.1 Product launches/enhancements/approvals 676
17.1.1.3.2 Deals 678
17.1.1.3.3 Expansions 680
17.1.1.3.4 Other developments 681
17.1.1.4 MnM view 681
17.1.1.4.1 Right to win 681
17.1.1.4.2 Strategic choices 681
17.1.1.4.3 Weaknesses & competitive threats 681
17.1.2 MICROSOFT CORPORATION 682
17.1.2.1 Business overview 682
17.1.2.2 Products & services offered 683
17.1.2.3 Recent developments 685
17.1.2.3.1 Product launches/enhancements/approvals 685
17.1.2.3.2 Deals 686
17.1.2.4 MnM view 688
17.1.2.4.1 Right to win 688
17.1.2.4.2 Strategic choices 688
17.1.2.4.3 Weaknesses & competitive threats 688
17.1.3 NVIDIA CORPORATION 689
17.1.3.1 Business overview 689
17.1.3.2 Products & services offered 690
17.1.3.3 Recent developments 691
17.1.3.3.1 Product launches/enhancements/approvals 691
17.1.3.3.2 Deals 692
17.1.3.4 MnM view 694
17.1.3.4.1 Right to win 694
17.1.3.4.2 Strategic choices 694
17.1.3.4.3 Weaknesses & competitive threats 694
17.1.4 SIEMENS HEALTHINEERS AG 695
17.1.4.1 Business overview 695
17.1.4.2 Products & services offered 696
17.1.4.3 Recent developments 698
17.1.4.3.1 Product launches/enhancements/approvals 698
17.1.4.3.2 Deals 699
 
17.1.4.4 MnM view 700
17.1.4.4.1 Right to win 700
17.1.4.4.2 Strategic choices 701
17.1.4.4.3 Weaknesses & competitive threats 701
17.1.5 GE HEALTHCARE 702
17.1.5.1 Business overview 702
17.1.5.2 Products & services offered 703
17.1.5.3 Recent developments 705
17.1.5.3.1 Product launches/enhancements/approvals 705
17.1.5.3.2 Deals 705
17.1.5.3.3 Other developments 707
17.1.5.4 MnM view 707
17.1.5.4.1 Right to win 707
17.1.5.4.2 Strategic choices 707
17.1.5.4.3 Weaknesses & competitive threats 707
17.1.6 EPIC SYSTEMS CORPORATION 708
17.1.6.1 Business overview 708
17.1.6.2 Products & services offered 708
17.1.6.3 Recent developments 709
17.1.6.3.1 Product launches/enhancements/approvals 709
17.1.6.3.2 Deals 709
17.1.7 ORACLE 710
17.1.7.1 Business overview 710
17.1.7.2 Products & services offered 711
17.1.7.3 Recent developments 712
17.1.7.3.1 Product launches/enhancements/approvals 712
17.1.7.3.2 Deals 713
17.1.7.3.3 Expansions 714
17.1.8 VERADIGM INC. 715
17.1.8.1 Business overview 715
17.1.8.2 Products & services offered 715
17.1.8.3 Recent developments 716
17.1.8.3.1 Product launches/enhancements/approvals 716
17.1.8.3.2 Deals 717
17.1.9 AMAZON WEB SERVICES, INC. 718
17.1.9.1 Business overview 718
17.1.9.2 Products & services offered 719
17.1.9.3 Recent developments 720
17.1.9.3.1 Product launches/enhancements/approvals 720
17.1.9.3.2 Deals 721
17.1.9.3.3 Expansions 722
 
17.1.10 MERATIVE 723
17.1.10.1 Business overview 723
17.1.10.2 Products & services offered 723
17.1.10.3 Recent developments 724
17.1.10.3.1 Product launches/enhancements/approvals 724
17.1.10.3.2 Deals 724
17.1.11 IBM 725
17.1.11.1 Business overview 725
17.1.11.2 Products & services offered 726
17.1.11.3 Recent developments 727
17.1.11.3.1 Deals 727
17.1.12 MEDTRONIC 728
17.1.12.1 Business overview 728
17.1.12.2 Products & services offered 729
17.1.12.3 Recent developments 730
17.1.12.3.1 Product launches/enhancements/approvals 730
17.1.12.3.2 Deals 731
17.1.13 GOOGLE 732
17.1.13.1 Business overview 732
17.1.13.2 Products & services offered 733
17.1.13.3 Recent developments 735
17.1.13.3.1 Product launches/enhancements/approvals 735
17.1.13.3.2 Deals 736
17.1.13.3.3 Other developments 738
17.1.14 SOPHIA GENETICS 739
17.1.14.1 Business overview 739
17.1.14.2 Products & services offered 740
17.1.14.3 Recent developments 740
17.1.14.3.1 Product launches/enhancements/approvals 740
17.1.14.3.2 Deals 741
17.1.14.3.3 Other developments 742
17.1.15 JOHNSON & JOHNSON SERVICES, INC. 743
17.1.15.1 Business overview 743
17.1.15.2 Products & services offered 744
17.1.15.3 Recent developments 745
17.1.15.3.1 Product launches/enhancements/approvals 745
17.1.15.3.2 Deals 745
17.1.16 TEMPUS AI, INC. 746
17.1.16.1 Business overview 746
17.1.16.2 Products & services offered 747
17.1.16.3 Recent developments 748
17.1.16.3.1 Product launches/enhancements/approvals 748
17.1.16.3.2 Deals 749
17.1.17 CONCERTAI 751
17.1.17.1 Business overview 751
17.1.17.2 Products & services offered 751
17.1.17.3 Recent developments 752
17.1.17.3.1 Product launches/enhancements/approvals 752
17.1.17.3.2 Deals 753
17.1.18 SOLVENTUM CORPORATION 755
17.1.18.1 Business overview 755
17.1.18.2 Products & services offered 756
17.1.18.3 Recent developments 757
17.1.18.3.1 Deals 757
17.1.18.3.2 Other developments 758
17.1.19 COGNIZANT 759
17.1.19.1 Business overview 759
17.1.19.2 Products & services offered 760
17.1.19.3 Recent developments 761
17.1.19.3.1 Product launches/enhancements/approvals 761
17.1.19.3.2 Deals 762
17.1.20 VIZ.AI, INC. 763
17.1.20.1 Business overview 763
17.1.20.2 Products & services offered 763
17.1.20.3 Recent developments 764
17.1.20.3.1 Product launches/enhancements/approvals 764
17.1.20.3.2 Deals 764
17.1.20.3.3 Other developments 766
17.1.21 RIVERAIN TECHNOLOGIES 767
17.1.21.1 Business overview 767
17.1.21.2 Products & services offered 767
17.1.21.3 Recent developments 768
17.1.21.3.1 Product launches/enhancements/approvals 768
17.1.21.3.2 Deals 768
17.2 OTHER PLAYERS 770
17.2.1 QVENTUS 770
17.2.2 QURE.AI 771
17.2.3 SUKI AI, INC. 772
17.2.4 ENLITIC 773
17.2.5 SEGMED 773
 
18 RESEARCH METHODOLOGY 774
18.1 RESEARCH DATA 774
18.1.1 SECONDARY DATA 775
18.1.1.1 Key data from secondary sources 776
18.1.2 PRIMARY DATA 776
18.1.2.1 Key data from primary sources 778
18.1.2.2 Key industry insights 778
18.2 MARKET SIZE ESTIMATION 779
18.3 DATA TRIANGULATION 784
18.4 MARKET SHARE ESTIMATION 785
18.5 RESEARCH ASSUMPTIONS 785
18.6 RESEARCH LIMITATIONS 785
18.6.1 METHODOLOGY-RELATED LIMITATIONS 785
18.6.2 SCOPE-RELATED LIMITATIONS 785
18.7 RISK ASSESSMENT 786
19 APPENDIX 787
19.1 DISCUSSION GUIDE 787
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 794
19.3 CUSTOMIZATION OPTI

ページTOPに戻る

List of Tables/Graphs

TABLE 1 INCLUSIONS AND EXCLUSIONS 68
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 72
TABLE 3 AI IN HEALTHCARE MARKET: IMPACT ANALYSIS 82
TABLE 4 ARTIFICIAL INTELLIGENCE IN HEALTHCARE MARKET: PORTER’S FIVE FORCES ANALYSIS 94
TABLE 5 AI IN HEALTHCARE MARKET: ROLE IN ECOSYSTEM 100
TABLE 6 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY NON-CLINICAL APPLICATION (2025) 101
TABLE 7 INDICATIVE PRICING FOR AI IN HEALTHCARE, BY CLINICAL APPLICATION (2025) 101
TABLE 8 CASE 1: AI-ENABLED LUNG CANCER DIAGNOSIS IN NHS HOSPITALS 104
TABLE 9 CASE 2: AI-DRIVEN PATIENT ENGAGEMENT IN CHILDREN'S HEALTHCARE 104
TABLE 10 CASE 3: DIGITAL PATIENT ENGAGEMENT AT SPARTA COMMUNITY HOSPITAL 105
TABLE 11 US-ADJUSTED RECIPROCAL TARIFF RATES 106
TABLE 12 EXPECTED CHANGE IN PRICES AND LIKELY IMPACT ON END-USE MARKET DUE TO TARIFF IMPACT 107
TABLE 13 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR AI IN HEALTHCARE SECTOR 114
TABLE 14 AI IN HEALTHCARE MARKET: LIST OF PATENTS/PATENT APPLICATIONS,
2022–2024 115
TABLE 15 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 118
TABLE 16 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 17 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119
TABLE 18 NORTH AMERICA 120
TABLE 19 EUROPE 121
TABLE 20 ASIA PACIFIC 121
TABLE 21 MIDDLE EAST & AFRICA 122
TABLE 22 LATIN AMERICA 123
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%) 125
TABLE 24 KEY BUYING CRITERIA FOR TOP 3 END USERS 126
TABLE 25 UNMET NEEDS IN AI IN HEALTHCARE MARKET 127
TABLE 26 END-USER EXPECTATIONS IN AI IN HEALTHCARE MARKET 128
TABLE 27 EXPECTED CHANGE IN PRICES AND ANTICIPATED IMPACT ON END USERS DUE TO TARIFF IMPACT 129
TABLE 28 AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 134
TABLE 29 AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION) 135
TABLE 30 AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 31 AI IN HEALTHCARE MARKET FOR PRE-SCREENING, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 32 AI IN HEALTHCARE MARKET FOR IVD, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 33 AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY,
2024–2031 (USD MILLION) 137
TABLE 34 AI IN HEALTHCARE MARKET FOR IMMUNOASSAYS, BY REGION,
2024–2031 (USD MILLION) 138
TABLE 35 AI IN HEALTHCARE MARKET FOR CLINICAL CHEMISTRY, BY REGION,
2024–2031 (USD MILLION) 139
TABLE 36 AI IN HEALTHCARE MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION,
2024–2031 (USD MILLION) 140
TABLE 37 AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION, 2024–2031 (USD MILLION) 140
TABLE 38 AI IN HEALTHCARE MARKET FOR IMAGE ANALYSIS & INTERPRETATION, BY REGION, 2024–2031 (USD MILLION) 141
TABLE 39 AI IN HEALTHCARE MARKET FOR BIOMARKER DISCOVERY & ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 40 AI IN HEALTHCARE MARKET FOR OTHER IVD APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 41 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 42 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION,
2024–2031 (USD MILLION) 144
TABLE 43 AI IN HEALTHCARE MARKET FOR DISEASE INTERPRETATION & REPORT ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 44 AI IN HEALTHCARE MARKET FOR IMAGE CAPTIONING & ANNOTATION, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 45 AI IN HEALTHCARE MARKET FOR IMAGE RECONSTRUCTION, BY REGION,
2024–2031 (USD MILLION) 147
TABLE 46 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSTIC IMAGING, BY REGION, 2024–2031 (USD MILLION) 147
TABLE 47 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY,
2024–2031 (USD MILLION) 148
TABLE 48 AI IN HEALTHCARE MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 49 AI IN HEALTHCARE MARKET FOR COMPUTED TOMOGRAPHY, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 50 AI IN HEALTHCARE MARKET FOR X-RAY IMAGING, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 51 AI IN HEALTHCARE MARKET FOR ULTRASOUND, BY REGION,
2024–2031 (USD MILLION) 152
TABLE 52 AI IN HEALTHCARE MARKET FOR NUCLEAR IMAGING, BY REGION,
2024–2031 (USD MILLION) 153
TABLE 53 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSTIC IMAGING MODALITIES,
BY REGION, 2024–2031 (USD MILLION) 153
TABLE 54 AI IN HEALTHCARE MARKET FOR RISK ASSESSMENT & PATIENT STRATIFICATION, BY REGION, 2024–2031 (USD MILLION) 154
TABLE 55 AI IN HEALTHCARE MARKET FOR DRUG ALLERGY ALERTING, BY REGION,
2024–2031 (USD MILLION) 155
TABLE 56 AI IN HEALTHCARE MARKET FOR OTHER DIAGNOSIS & EARLY DETECTION FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 156
TABLE 57 AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION,
BY TYPE, 2024–2031 (USD MILLION) 156
TABLE 58 AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION,
BY REGION, 2024–2031 (USD MILLION) 157
TABLE 59 AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION) 158
TABLE 60 AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING,
BY REGION, 2024–2031 (USD MILLION) 158
TABLE 61 AI IN HEALTHCARE MARKET FOR PRECISION MEDICINE & GENOMIC ANALYSIS,
BY REGION, 2024–2031 (USD MILLION) 159
TABLE 62 AI IN HEALTHCARE MARKET FOR PREDICTIVE MODELS FOR TREATMENT RESPONSE, BY REGION, 2024–2031 (USD MILLION) 160
TABLE 63 AI IN HEALTHCARE MARKET FOR TREATMENT RECOMMENDATION SYSTEMS,
BY REGION, 2024–2031 (USD MILLION) 161
TABLE 64 AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE,
2024–2031 (USD MILLION) 161
TABLE 65 AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY REGION, 2024–2031 (USD MILLION) 162
TABLE 66 AI IN HEALTHCARE MARKET FOR DRUG RESPONSE PREDICTION, BY REGION, 2024–2031 (USD MILLION) 163
TABLE 67 AI IN HEALTHCARE MARKET FOR DOSING & ADMINISTRATION, BY REGION,
2024–2031 (USD MILLION) 164
TABLE 68 AI IN HEALTHCARE MARKET FOR OTHER PHARMACOLOGICAL THERAPY FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 164
TABLE 69 AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE,
2024–2031 (USD MILLION) 165
TABLE 70 AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY REGION,
2024–2031 (USD MILLION) 165
TABLE 71 AI IN HEALTHCARE MARKET FOR PREOPERATIVE IMAGING & 3D MODELING,
BY REGION, 2024–2031 (USD MILLION) 166
TABLE 72 AI IN HEALTHCARE MARKET FOR INTRAOPERATIVE GUIDANCE & ROBOTICS,
BY REGION, 2024–2031 (USD MILLION) 167
TABLE 73 AI IN HEALTHCARE MARKET FOR POSTOPERATIVE ANALYSIS & RECOVERY,
BY REGION, 2024–2031 (USD MILLION) 168
TABLE 74 AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE,
2024–2031 (USD MILLION) 169
TABLE 75 AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY REGION,
2024–2031 (USD MILLION) 169
TABLE 76 AI IN HEALTHCARE MARKET FOR MOTION SYNCHRONIZATION & AUTO CONTOURING, BY REGION, 2024–2031 (USD MILLION) 170
TABLE 77 AI IN HEALTHCARE MARKET FOR REAL-TIME ADAPTIVE TREATMENT DELIVERY,
BY REGION, 2024–2031 (USD MILLION) 171
TABLE 78 AI IN HEALTHCARE MARKET FOR RESPONSE ASSESSMENT & QUALITY ASSURANCE, BY REGION, 2024–2031 (USD MILLION) 172
TABLE 79 AI IN HEALTHCARE MARKET FOR OTHER RADIATION THERAPY FUNCTIONS,
BY REGION, 2024–2031 (USD MILLION) 172
TABLE 80 AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY,
BY TYPE, 2024–2031 (USD MILLION) 173
TABLE 81 AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY,
BY REGION, 2024–2031 (USD MILLION) 173
TABLE 82 AI IN HEALTHCARE MARKET FOR VIRTUAL COUNSELING & CHATBOTS, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 83 AI IN HEALTHCARE MARKET FOR PROGRESS MONITORING & FEEDBACK,
BY REGION, 2024–2031 (USD MILLION) 175
TABLE 84 AI IN HEALTHCARE MARKET FOR FOLLOW-UP & LONG-TERM SUPPORT, BY REGION, 2024–2031 (USD MILLION) 176
TABLE 85 AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE,
2024–2031 (USD MILLION) 177
TABLE 86 AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY REGION,
2024–2031 (USD MILLION) 177
TABLE 87 AI IN HEALTHCARE MARKET FOR REAL-TIME PATIENT DATA MONITORING,
BY REGION, 2024–2031 (USD MILLION) 178
TABLE 88 AI IN HEALTHCARE MARKET FOR RESPONSE & SIDE-EFFECT PREDICTION,
BY REGION, 2024–2031 (USD MILLION) 179
TABLE 89 AI IN HEALTHCARE MARKET FOR RELAPSE PREDICTION & LONG-TERM MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 180
TABLE 90 AI IN HEALTHCARE MARKET FOR OTHER TREATMENT PLANNING & PERSONALIZATION FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 180
TABLE 91 AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION) 181
TABLE 92 AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY REGION, 2024–2031 (USD MILLION) 182
TABLE 93 AI IN HEALTHCARE MARKET FOR SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE, BY REGION, 2024–2031 (USD MILLION) 183
TABLE 94 AI IN HEALTHCARE MARKET FOR TELEHEALTH & REMOTE PATIENT MONITORING, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 95 AI IN HEALTHCARE MARKET FOR HEALTHCARE ASSISTANCE ROBOTS, BY REGION, 2024–2031 (USD MILLION) 185
TABLE 96 AI IN HEALTHCARE MARKET FOR MEDICATION REMINDERS, BY REGION,
2024–2031 (USD MILLION) 186
TABLE 97 AI IN HEALTHCARE MARKET FOR PATIENT EDUCATION & EMPOWERMENT,
BY REGION, 2024–2031 (USD MILLION) 187
TABLE 98 AI IN HEALTHCARE MARKET FOR OTHER PATIENT ENGAGEMENT & REMOTE MONITORING FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 187
TABLE 99 AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION) 188
TABLE 100 AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY REGION, 2024–2031 (USD MILLION) 188
TABLE 101 AI IN HEALTHCARE MARKET FOR RECURRENCE MONITORING, BY REGION,
2024–2031 (USD MILLION) 189
TABLE 102 AI IN HEALTHCARE MARKET FOR LONG-TERM OUTCOME PREDICTION, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 103 AI IN HEALTHCARE MARKET FOR MENTAL HEALTH & SUPPORT SYSTEMS,
BY REGION, 2024–2031 (USD MILLION) 191
TABLE 104 AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE,
2024–2031 (USD MILLION) 191
TABLE 105 AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY REGION, 2
024–2031 (USD MILLION) 192
TABLE 106 AI IN HEALTHCARE MARKET FOR EPRESCRIBING, BY REGION,
2024–2031 (USD MILLION) 193
TABLE 107 AI IN HEALTHCARE MARKET FOR MEDICATION MANAGEMENT, BY REGION,
2024–2031 (USD MILLION) 194
TABLE 108 AI IN HEALTHCARE MARKET FOR PHARMACY AUDIT & ANALYSIS, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 109 AI IN HEALTHCARE MARKET FOR OTHER PHARMACY MANAGEMENT FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 195
TABLE 110 AI IN HEALTHCARE MARKET FOR DATA MANAGEMENT & ANALYTICS FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 196
TABLE 111 AI IN HEALTHCARE MARKET FOR AI SCRIBE, BY REGION,
2024–2031 (USD MILLION) 197
TABLE 112 AI IN HEALTHCARE MARKET FOR CLINICAL DECISION SUPPORT SYSTEMS,
BY REGION, 2024–2031 (USD MILLION) 198
TABLE 113 AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION) 199
TABLE 114 AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY REGION,
2024–2031 (USD MILLION) 199
TABLE 115 AI IN HEALTHCARE MARKET FOR PATIENT REGISTRATION & SCHEDULING,
BY REGION, 2024–2031 (USD MILLION) 200
TABLE 116 AI IN HEALTHCARE MARKET FOR PATIENT ELIGIBILITY & AUTHORIZATION,
BY REGION, 2024–2031 (USD MILLION) 201
TABLE 117 AI IN HEALTHCARE MARKET FOR REVENUE CYCLE MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 202
TABLE 118 AI IN HEALTHCARE MARKET FOR WORKFORCE MANAGEMENT, BY REGION,
2024–2031 (USD MILLION) 203
TABLE 119 AI IN HEALTHCARE MARKET FOR SUPPLY CHAIN & INVENTORY MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION) 204
TABLE 120 AI IN HEALTHCARE MARKET FOR COMPLIANCE & DOCUMENTATION, BY REGION, 2024–2031 (USD MILLION) 205
TABLE 121 AI IN HEALTHCARE MARKET FOR HEALTHCARE WORKFLOW MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION) 206
TABLE 122 AI IN HEALTHCARE MARKET FOR ASSET MANAGEMENT, BY REGION,
2024–2031 (USD MILLION) 207
TABLE 123 AI IN HEALTHCARE MARKET FOR CUSTOMER RELATIONSHIP MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION) 208
TABLE 124 AI IN HEALTHCARE MARKET FOR FRAUD DETECTION & RISK MANAGEMENT,
BY REGION, 2024–2031 (USD MILLION) 209
TABLE 125 AI IN HEALTHCARE MARKET FOR CYBERSECURITY, BY REGION,
2024–2031 (USD MILLION) 210
TABLE 126 AI IN HEALTHCARE MARKET FOR OTHER ADMINISTRATIVE FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 210
TABLE 127 AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 212
TABLE 128 AI IN HEALTHCARE MARKET FOR INTEGRATED SOLUTIONS, BY REGION,
2024–2031 (USD MILLION) 213
TABLE 129 AI IN HEALTHCARE MARKET FOR NICHE/POINT SOLUTIONS, BY REGION,
2024–2031 (USD MILLION) 214
TABLE 130 AI IN HEALTHCARE MARKET FOR AI TECHNOLOGIES, BY REGION,
2024–2031 (USD MILLION) 215
TABLE 131 AI IN HEALTHCARE MARKET FOR SERVICES, BY REGION,
2024–2031 (USD MILLION) 216
TABLE 132 AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218
TABLE 133 AI IN HEALTHCARE MARKET FOR CLINICAL APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 219
TABLE 134 AI IN HEALTHCARE MARKET FOR NON-CLINICAL APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 221
TABLE 135 AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL,
2024–2031 (USD MILLION) 223
TABLE 136 AI IN HEALTHCARE MARKET FOR ON-PREMISES MODEL, BY REGION,
2024–2031 (USD MILLION) 224
TABLE 137 AI IN HEALTHCARE MARKET FOR CLOUD-BASED MODEL, BY REGION,
2024–2031 (USD MILLION) 225
TABLE 138 AI IN HEALTHCARE MARKET FOR HYBRID MODEL, BY REGION,
2024–2031 (USD MILLION) 226
TABLE 139 AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION) 228
TABLE 140 AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE,
2024–2031 (USD MILLION) 229
TABLE 141 AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY REGION,
2024–2031 (USD MILLION) 229
TABLE 142 AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE,
2024–2031 (USD MILLION) 231
TABLE 143 AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY REGION,
2024–2031 (USD MILLION) 231
TABLE 144 AI IN HEALTHCARE MARKET FOR CONVOLUTIONAL NEURAL NETWORKS,
BY REGION, 2024–2031 (USD MILLION) 232
TABLE 145 AI IN HEALTHCARE MARKET FOR RECURRENT NEURAL NETWORKS, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 146 AI IN HEALTHCARE MARKET FOR GENERATIVE ADVERSARIAL NETWORKS,
BY REGION, 2024–2031 (USD MILLION) 234
TABLE 147 AI IN HEALTHCARE MARKET FOR GRAPH NEURAL NETWORKS, BY REGION,
2024–2031 (USD MILLION) 235
TABLE 148 AI IN HEALTHCARE MARKET FOR OTHER DEEP LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION) 235
TABLE 149 AI IN HEALTHCARE MARKET FOR SUPERVISED LEARNING, BY REGION,
2024–2031 (USD MILLION) 236
TABLE 150 AI IN HEALTHCARE MARKET FOR REINFORCEMENT LEARNING, BY REGION,
2024–2031 (USD MILLION) 237
TABLE 151 AI IN HEALTHCARE MARKET FOR UNSUPERVISED LEARNING, BY REGION,
2024–2031 (USD MILLION) 238
TABLE 152 AI IN HEALTHCARE MARKET FOR OTHER MACHINE LEARNING TOOLS, BY REGION, 2024–2031 (USD MILLION) 239
TABLE 153 AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 154 AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2024–2031 (USD MILLION) 240
TABLE 155 AI IN HEALTHCARE MARKET FOR SENTIMENT ANALYSIS, BY REGION,
2024–2031 (USD MILLION) 241
TABLE 156 AI IN HEALTHCARE MARKET FOR PATTERN & IMAGE RECOGNITION, BY REGION, 2024–2031 (USD MILLION) 242
TABLE 157 AI IN HEALTHCARE MARKET FOR AUTO CODING, BY REGION,
2024–2031 (USD MILLION) 243
TABLE 158 AI IN HEALTHCARE MARKET FOR CLASSIFICATION & CATEGORIZATION, BY REGION, 2024–2031 (USD MILLION) 243
TABLE 159 AI IN HEALTHCARE MARKET FOR TEXT ANALYTICS, BY REGION,
2024–2031 (USD MILLION) 244
TABLE 160 AI IN HEALTHCARE MARKET FOR SPEECH RECOGNITION, BY REGION,
2024–2031 (USD MILLION) 245
TABLE 161 AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE,
2024–2031 (USD MILLION) 246
TABLE 162 AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY REGION, 2024–2031 (USD MILLION) 246
TABLE 163 AI IN HEALTHCARE MARKET FOR DEVICE CONTEXT, BY REGION,
2024–2031 (USD MILLION) 247
TABLE 164 AI IN HEALTHCARE MARKET FOR USER CONTEXT, BY REGION,
2024–2031 (USD MILLION) 248
TABLE 165 AI IN HEALTHCARE MARKET FOR PHYSICAL CONTEXT, BY REGION,
2024–2031 (USD MILLION) 248
TABLE 166 AI IN HEALTHCARE MARKET FOR GENERATIVE AI, BY REGION,
2024–2031 (USD MILLION) 249
TABLE 167 AI IN HEALTHCARE MARKET FOR COMPUTER VISION, BY REGION,
2024–2031 (USD MILLION) 250
TABLE 168 AI IN HEALTHCARE MARKET FOR IMAGE ANALYSIS, BY REGION,
2024–2031 (USD MILLION) 251
TABLE 169 AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION) 253
TABLE 170 AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,
2024–2031 (USD MILLION) 254
TABLE 171 AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY REGION,
2024–2031 (USD MILLION) 255
TABLE 172 AI IN HEALTHCARE MARKET FOR HOSPITALS & CLINICS, BY REGION,
2024–2031 (USD MILLION) 256
TABLE 173 AI IN HEALTHCARE MARKET FOR AMBULATORY CARE CENTERS, BY REGION, 2024–2031 (USD MILLION) 257
TABLE 174 AI IN HEALTHCARE MARKET FOR HOME HEALTHCARE AGENCIES & ASSISTED-LIVING FACILITIES, BY REGION, 2024–2031 (USD MILLION) 258
TABLE 175 AI IN HEALTHCARE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2024–2031 (USD MILLION) 259
TABLE 176 AI IN HEALTHCARE MARKET FOR PHARMACIES, BY REGION,
2024–2031 (USD MILLION) 260
TABLE 177 AI IN HEALTHCARE MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2024–2031 (USD MILLION) 260
TABLE 178 AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION) 261
TABLE 179 AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY REGION,
2024–2031 (USD MILLION) 261
TABLE 180 AI IN HEALTHCARE MARKET FOR PUBLIC PAYERS, BY REGION,
2024–2031 (USD MILLION) 262
TABLE 181 AI IN HEALTHCARE MARKET FOR PRIVATE PAYERS, BY REGION,
2024–2031 (USD MILLION) 263
TABLE 182 AI IN HEALTHCARE MARKET FOR PATIENTS, BY REGION,
2024–2031 (USD MILLION) 264
TABLE 183 AI IN HEALTHCARE MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 265
TABLE 184 AI IN HEALTHCARE MARKET, BY REGION, 2024–2031 (USD MILLION) 267
TABLE 185 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 270
TABLE 186 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY OFFERING,
2024–2031 (USD MILLION) 270
TABLE 187 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY FUNCTION,
2024–2031 (USD MILLION) 271
TABLE 188 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 189 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY,
2024–2031 (USD MILLION) 272
TABLE 190 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION,
2024–2031 (USD MILLION) 272
TABLE 191 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING,
BY APPLICATION, 2024–2031 (USD MILLION) 273
TABLE 192 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING,
BY MODALITY, 2024–2031 (USD MILLION) 273
TABLE 193 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 194 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 195 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 196 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 197 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 198 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 199 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 200 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 201 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 202 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT,
BY TYPE, 2024–2031 (USD MILLION) 278
TABLE 203 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 204 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 279
TABLE 205 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL,
2024–2031 (USD MILLION) 280
TABLE 206 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY TOOL,
2024–2031 (USD MILLION) 280
TABLE 207 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 208 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE, 2024–2031 (USD MILLION) 281
TABLE 209 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 210 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 211 NORTH AMERICA: AI IN HEALTHCARE MARKET, BY END USER,
2024–2031 (USD MILLION) 283
TABLE 212 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS,
BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 213 NORTH AMERICA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE, 2024–2031 (USD MILLION) 284
TABLE 214 US: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 285
TABLE 215 US: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 285
TABLE 216 US: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2024–2031 (USD MILLION) 286
TABLE 217 US: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY,
2024–2031 (USD MILLION) 286
TABLE 218 US: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION,
2024–2031 (USD MILLION) 287
TABLE 219 US: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION) 287
TABLE 220 US: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY,
2024–2031 (USD MILLION) 288
TABLE 221 US: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION) 288
TABLE 222 US: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING,
BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 223 US: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 224 US: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE,
2024–2031 (USD MILLION) 290
TABLE 225 US: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE,
2024–2031 (USD MILLION) 290
TABLE 226 US: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION) 291
TABLE 227 US: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE,
2024–2031 (USD MILLION) 291
TABLE 228 US: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 229 US: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 230 US: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE,
2024–2031 (USD MILLION) 293
TABLE 231 US: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION) 293
TABLE 232 US: AI IN HEALTHCARE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 294
TABLE 233 US: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL,
2024–2031 (USD MILLION) 294
TABLE 234 US: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION) 294
TABLE 235 US: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE,
2024–2031 (USD MILLION) 295
TABLE 236 US: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE,
2024–2031 (USD MILLION) 295
TABLE 237 US: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 238 US: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 239 US: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION) 297
TABLE 240 US: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,
2024–2031 (USD MILLION) 297
TABLE 241 US: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION) 298
TABLE 242 CANADA: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 299
TABLE 243 CANADA: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 299
TABLE 244 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION,
BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 245 CANADA: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY,
2024–2031 (USD MILLION) 300
TABLE 246 CANADA: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION,
2024–2031 (USD MILLION) 301
TABLE 247 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION) 301
TABLE 248 CANADA: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION) 302
TABLE 249 CANADA: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 250 CANADA: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 251 CANADA: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION) 303
TABLE 252 CANADA: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 253 CANADA: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE,
2024–2031 (USD MILLION) 304
TABLE 254 CANADA: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION) 305
TABLE 255 CANADA: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE,
2024–2031 (USD MILLION) 305
TABLE 256 CANADA: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 257 CANADA: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION) 306
TABLE 258 CANADA: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 259 CANADA: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION) 307
TABLE 260 CANADA: AI IN HEALTHCARE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 308
TABLE 261 CANADA: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL,
2024–2031 (USD MILLION) 308
TABLE 262 CANADA: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION) 308
TABLE 263 CANADA: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE,
2024–2031 (USD MILLION) 309
TABLE 264 CANADA: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE,
2024–2031 (USD MILLION) 309
TABLE 265 CANADA: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING,
BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 266 CANADA: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING, BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 267 CANADA: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION) 311
TABLE 268 CANADA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 269 CANADA: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION) 312
TABLE 270 EUROPE: AI IN HEALTHCARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 313
TABLE 271 EUROPE: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 313
TABLE 272 EUROPE: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 314
TABLE 273 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION,
BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 274 EUROPE: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY,
2024–2031 (USD MILLION) 315
TABLE 275 EUROPE: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION,
2024–2031 (USD MILLION) 315
TABLE 276 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY APPLICATION, 2024–2031 (USD MILLION) 316
TABLE 277 EUROPE: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION) 316
TABLE 278 EUROPE: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 279 EUROPE: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION) 317
TABLE 280 EUROPE: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY, BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 281 EUROPE: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE,
2024–2031 (USD MILLION) 318
TABLE 282 EUROPE: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE,
2024–2031 (USD MILLION) 319
TABLE 283 EUROPE: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION) 319
TABLE 284 EUROPE: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE,
2024–2031 (USD MILLION) 320
TABLE 285 EUROPE: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 286 EUROPE: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 287 EUROPE: AI IN HEALTHCARE MARKET FOR PHARMACY MANAGEMENT, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 288 EUROPE: AI IN HEALTHCARE MARKET FOR ADMINISTRATIVE, BY TYPE,
2024–2031 (USD MILLION) 322
TABLE 289 EUROPE: AI IN HEALTHCARE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 322
TABLE 290 EUROPE: AI IN HEALTHCARE MARKET, BY DEPLOYMENT MODEL,
2024–2031 (USD MILLION) 323
TABLE 291 EUROPE: AI IN HEALTHCARE MARKET, BY TOOL, 2024–2031 (USD MILLION) 323
TABLE 292 EUROPE: AI IN HEALTHCARE MARKET FOR MACHINE LEARNING, BY TYPE,
2024–2031 (USD MILLION) 324
TABLE 293 EUROPE: AI IN HEALTHCARE MARKET FOR DEEP LEARNING, BY TYPE,
2024–2031 (USD MILLION) 324
TABLE 294 EUROPE: AI IN HEALTHCARE MARKET FOR NATURAL LANGUAGE PROCESSING,
BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 295 EUROPE: AI IN HEALTHCARE MARKET FOR CONTEXT-AWARE COMPUTING,
BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 296 EUROPE: AI IN HEALTHCARE MARKET, BY END USER, 2024–2031 (USD MILLION) 326
TABLE 297 EUROPE: AI IN HEALTHCARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2024–2031 (USD MILLION) 326
TABLE 298 EUROPE: AI IN HEALTHCARE MARKET FOR HEALTHCARE PAYERS, BY TYPE,
2024–2031 (USD MILLION) 327
TABLE 299 GERMANY: AI IN HEALTHCARE MARKET, BY OFFERING, 2024–2031 (USD MILLION) 328
TABLE 300 GERMANY: AI IN HEALTHCARE MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 328
TABLE 301 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSIS & EARLY DETECTION,
BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 302 GERMANY: AI IN HEALTHCARE MARKET FOR IVD, BY TECHNOLOGY,
2024–2031 (USD MILLION) 329
TABLE 303 GERMANY: AI IN HEALTHCARE MARKET FOR IVD, BY APPLICATION,
2024–2031 (USD MILLION) 330
TABLE 304 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING,
BY APPLICATION, 2024–2031 (USD MILLION) 330
TABLE 305 GERMANY: AI IN HEALTHCARE MARKET FOR DIAGNOSTIC IMAGING, BY MODALITY, 2024–2031 (USD MILLION) 331
TABLE 306 GERMANY: AI IN HEALTHCARE MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2024–2031 (USD MILLION) 331
TABLE 307 GERMANY: AI IN HEALTHCARE MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 308 GERMANY: AI IN HEALTHCARE MARKET FOR PHARMACOLOGICAL THERAPY,
BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 309 GERMANY: AI IN HEALTHCARE MARKET FOR SURGICAL THERAPY, BY TYPE,
2024–2031 (USD MILLION) 333
TABLE 310 GERMANY: AI IN HEALTHCARE MARKET FOR RADIATION THERAPY, BY TYPE, 2024–2031 (USD MILLION) 333
TABLE 311 GERMANY: AI IN HEALTHCARE MARKET FOR BEHAVIORAL THERAPY & PSYCHOTHERAPY, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 312 GERMANY: AI IN HEALTHCARE MARKET FOR IMMUNOTHERAPY, BY TYPE,
2024–2031 (USD MILLION) 334
TABLE 313 GERMANY: AI IN HEALTHCARE MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2024–2031 (USD MILLION) 335
TABLE 314 GERMANY: AI IN HEALTHCARE MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY T